Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allisartan medoxomil + amlodipine is a fixed-dose combination antihypertensive medication containing two active ingredients: - **Allisartan medoxomil** is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, leading to vasodilation and reduced blood pressure. - **Amlodipine** is a dihydropyridine calcium channel blocker (CCB) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in relaxation of blood vessels and further lowering of blood pressure. This combination targets two different mechanisms involved in hypertension, providing additive or synergistic effects for better control of high blood pressure. The primary indication for this drug is the treatment of hypertension (high blood pressure).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allisartan medoxomil + amlodipine.